Antipsychotic Injections: Comparing Your Treatment Options

Two injections that contain the same antipsychotic can have different starts, schedules, and approved uses. This second part of the NP FADY series compares the long-acting antipsychotic injections available in the United States, checked against current FDA labels and access notices on September 30, 2026.

What to know

• Pick the medicine first, then the version. Risperidone, aripiprazole, paliperidone, olanzapine, haloperidol, and fluphenazine each come in long-acting forms, and versions of the same drug differ in start, schedule, and approved uses.[1,2,3]
• Schedules range from every 2 weeks to every 6 months. Invega Hafyera is given every 6 months, but only after adequate treatment with a monthly paliperidone injection for at least four months or one 3-month Invega Trinza cycle.[4]
• Starts differ. Risperdal Consta needs 3 weeks of oral coverage and Rykindo 7 days; Abilify Maintena, Abilify Asimtufii, and Aristada (with Aristada Initio) offer one-day starts.[5,6,7,8,9,10]
• Zyprexa Relprevv requires at least 3 hours of observation in a certified setting after every injection because of a risk of severe sedation or delirium.[11]
• Perseris is no longer supplied. Indivior discontinued availability effective May 31, 2026, not for safety or efficacy reasons, so people receiving it need a transition plan.[12]
• A new option arrived in October 2026. The FDA approved Weltruza, Teva’s monthly under-the-skin olanzapine injection, on October 8, 2026, and Teva said it would be available in the coming weeks.[13,29]

Zoom

Overview

The best long-acting injection is the one that combines an effective medicine with a schedule, side-effect profile, and care plan you can live with. A six-month injection may sound ideal. A monthly option may fit better if your treatment is still changing. Someone who does well with a particular pill may want to keep that medicine rather than change drugs for a longer interval.

This article compares US products. Part 1 explains how these medicines work and what the research shows. Part 3 covers safety, missed appointments, monitoring, and family support. Brand names matter here: two injections containing the same active drug can have different starts, schedules, and approved uses.

First choose the medicine, then the delivery system

There are two decisions to make with your prescriber: which active drug fits your needs, and which version of that drug fits your life. Prior response, unwanted effects, other medicines, and physical health matter alongside appointment frequency. NICE’s schizophrenia guideline, a UK guideline rather than a US approval standard, specifically includes patient preferences and the practical arrangements for injections in this discussion.[14]

Intramuscular, or IM, means into a muscle. Subcutaneous, or SC, means under the skin. Neither route automatically promises less pain or fewer whole-body side effects. The injection site is product-specific. An arm injection may mean into the shoulder muscle for one product and under the skin for another.

An FDA approval describes the condition, population, and treatment phase supported by that product’s label. It is not a promise that your pharmacy has stock or your plan covers it. Current labels and access notices were checked for this series. Local supplies and coverage still require confirmation.

These medicines carry boxed warnings about increased death risk in older adults with dementia-related psychosis. None of the injections in this comparison is approved for that use. This warning should remain part of an individual benefit-risk discussion.[1,5,6,11,15,16]

LAI options at a glance: schedules and approved uses

The table describes usual maintenance schedules. Starting treatment can require pills, extra injections, or prior treatment on another formulation. The next table explains those differences. “Bipolar maintenance” means ongoing treatment to reduce recurrence; it does not mean an injection is approved for every bipolar episode or symptom.

PERSERIS is discussed separately below because its manufacturer has discontinued availability. ARISTADA INITIO is a starter or restart product, rather than a regular maintenance choice.[10,12]

Why the first month can look different: starting requirements

An oral tolerability check means taking the medicine by mouth first to assess your response and unwanted effects. Oral overlap means taking pills after the first injection while the injectable treatment gets underway. These are different steps. A product without routine oral overlap can still require an oral tolerability check.

The table summarizes usual starts, not individualized switching or missed-dose instructions. Your current treatment, organ function, and interacting medicines can change the plan. Do not stop pills based on this table.

Risperidone injections: Risperdal Consta, Rykindo, Uzedy, and Perseris

RISPERDAL CONSTA

CONSTA can preserve risperidone treatment when daily pills are burdensome. It is given into the shoulder or buttock muscle. The two-week schedule means frequent appointments, which may fit someone who values regular contact but can be difficult with work or transportation.

Its delayed main release explains the three-week oral coverage requirement. Kidney or liver impairment requires careful oral titration before the injection. Potential problems include raised prolactin, weight or metabolic changes, sleepiness, and movement symptoms. Prolactin is a hormone; changes can affect sexual function or periods. A useful question is whether the benefit you already get from risperidone outweighs these concerns.[6]

Generic versions of the CONSTA-type two-week injection are also relevant. Lupin announced a US launch in November 2025, and current Lupin and Amneal labels were identified. Ask the pharmacist which specific product is being supplied; “risperidone injection” alone does not identify the formulation.[18,19,20]

RYKINDO

RYKINDO uses risperidone but has a different release pattern from CONSTA. It also involves a visit every two weeks, but the labeled oral coverage at a usual first start is one week. It is given into the buttock muscle, rather than offering CONSTA’s shoulder option.

The shorter oral bridge can matter if managing several weeks of pills is difficult. It does not remove the need to show oral tolerability or review kidney and liver function. The shared risperidone concerns still apply, including prolactin changes, weight/metabolic effects, and movement symptoms. If you already receive CONSTA, your clinician must use RYKINDO’s specific transition instructions. An identical interval does not make the two products interchangeable at the next visit without planning.[7]

UZEDY

UZEDY’s bipolar I maintenance schedule is monthly only. For schizophrenia, the table shows both intervals. Its under-the-skin injection sites are the abdomen or upper arm.[3]

A start without routine extra pills may simplify your early routine. Ask the team to walk through the calendar rather than assuming fewer pills means fewer checks. Discuss itching or a nodule, kidney or liver conditions, and interacting medicines. Which schedule fits your diagnosis, and are you comfortable with the injection site?[3]

PERSERIS: an access change that needs a transition plan

PERSERIS was a monthly under-the-skin risperidone treatment for adult schizophrenia, usually without loading or oral overlap after tolerability was established.[21]

Indivior’s official notice says availability was discontinued effective May 31, 2026. It says the decision was not due to safety or efficacy problems. The notice mentioned possible residual supplier stock for a few months after discontinuation. Remaining stock as of September 30, 2026, was not verified. A remaining label or product website does not override that notice. If you receive PERSERIS, contact your prescriber about an alternative and the timing of the change. Do not assume another risperidone injection can replace it dose for dose.[12]

Aripiprazole injections: Abilify Maintena, Abilify Asimtufii, and Aristada

ABILIFY MAINTENA

Ask whether this treatment is intended to be used alone or alongside other medicine for your diagnosis. That question helps clarify how it fits your whole plan. The table gives MAINTENA’s specific approved uses.[5]

Compare the two starting options in the table with your team. Would temporary daily pills be practical, or would more injections at the first visit be a burden? Ask how other medicines or differences in drug processing affect your plan. Discuss restlessness, weight changes, sleepiness, and unusual new urges such as gambling or compulsive shopping.[5,22]

ABILIFY ASIMTUFII

ASIMTUFII may appeal when frequent appointments interfere with work, caregiving, or transport. Review its specific starting row with the prescriber, including whether you are switching from MAINTENA or starting from oral treatment. Which practical problem would the longer schedule solve for you?[8]

The longer schedule may suit someone who has an established response and finds frequent visits difficult. Familiarity with aripiprazole’s tolerability is valuable. Fewer injection visits do not by themselves show better effectiveness. Review interactions and the same aripiprazole-related concerns before choosing it.[8]

ARISTADA and ARISTADA INITIO

ARISTADA contains aripiprazole lauroxil, which the body converts into aripiprazole. It is approved for adult schizophrenia, not bipolar maintenance. Its possible schedules depend on the strength: monthly, six-week, and two-month options cannot be selected independently of the dose. The lowest strength can be given in the shoulder or buttock; other strengths are buttock injections.

Use the starting table to discuss whether a pill bridge or a separate starter injection fits your circumstances. Confirm who supplies each medicine and how the visits will be scheduled. Restlessness and aripiprazole’s other warnings still need consideration.[9,22]

INITIO is a one-time starter or restart injection. It is not the maintenance drug and is not interchangeable with ARISTADA. Certain strong drug interactions or known differences in metabolism can make INITIO unsuitable. Ask for the exact names of every injection in the starting plan.[10]

Paliperidone injections: Invega Sustenna, Erzofri, Trinza, and Hafyera

INVEGA SUSTENNA

SUSTENNA’s starting row deserves attention when arranging time off or a ride. Make sure the clinic can supply the medicine and accommodate both initial visits. Ask which injection site will be used during the start and during maintenance.[1]

The first-week return visit is a practical consideration. Its separate schizoaffective approval also matters when comparing products. Kidney function affects dosing and eligibility: it is not recommended with moderate or severe kidney impairment. Discuss prolactin-related symptoms, weight/metabolic changes, movement symptoms, and heart-rhythm risk where relevant. An established SUSTENNA response may later support a discussion about a longer-interval product, but this is a separate decision.[1]

ERZOFRI

ERZOFRI is another monthly paliperidone palmitate product approved for adult schizophrenia and schizoaffective disorder. Its distinguishing starting feature is a single initial shoulder injection rather than SUSTENNA’s two-injection first-week regimen. Maintenance injections can use the shoulder or buttock.

That can avoid a second initiation visit, but it does not bypass oral tolerability assessment for previously unexposed patients or kidney-function review. Moderate/severe kidney impairment makes it unsuitable under its label, and mild impairment changes the start. Paliperidone’s prolactin, metabolic, movement, and heart-rhythm concerns remain relevant. Its approval relies on studies of another monthly paliperidone formulation. It is a separately labeled product, not permission to use SUSTENNA’s starting instructions.[2]

INVEGA TRINZA

TRINZA extends the interval to three months for people with schizophrenia after adequate SUSTENNA treatment. It can use the shoulder or buttock muscle. At least four months of SUSTENNA treatment are required, and the label recommends the last two monthly doses be the same strength.

For someone doing well with paliperidone, fewer injections may ease scheduling without changing the active medicine. The main tradeoff is committing to a longer exposure when adjustment may be needed. Kidney function and the prior dose affect eligibility. TRINZA does not carry SUSTENNA’s schizoaffective indication. Ask whether your current response is established enough for this step and how the team would manage a late injection or unwanted effect.[17]

INVEGA HAFYERA

Review HAFYERA’s qualifying-treatment row in the starting table with your prescriber. Ask which prior product and strength count, whether your response is established, and whether your kidney function permits this choice. Not every preceding dose has a HAFYERA equivalent.[4]

Two injections per year can reduce injection appointments, but it does not mean two care contacts per year. Monitoring and symptom follow-up still matter. A change cannot quickly remove the medication already delivered. Kidney-function restrictions, including special caution in older adults, need close review. Ask whether the longer interval serves your goals now, and what follow-up will occur between injections.[4]

Olanzapine injection: Zyprexa Relprevv and its observation requirement

ZYPREXA RELPREVV

RELPREVV offers long-acting olanzapine for schizophrenia through a buttock muscle injection. It may be worth discussing when olanzapine has helped, but its visit requirements are substantial.

After every dose, a certified setting must provide at least three hours of continuous observation, and you must be accompanied to your destination afterward. Prescriber, patient, setting, and pharmacy enrollment in the REMS program is required.[11,23]

Staff must assess you before release. The reason is post-injection delirium/sedation syndrome, which can cause severe confusion or sleepiness, including coma.[11]

Weight, glucose, lipid, and sedation concerns also remain. Plan transportation and time away from work. Do not drive that day. This is a current restricted-program option; do not confuse it with short-acting olanzapine injections used for agitation.[11]

Haloperidol and fluphenazine decanoate

Haloperidol decanoate

Haloperidol decanoate is an established generic option. The current label reviewed uses deep muscle injections every four weeks for adults with schizophrenia who were previously taking a stable oral haloperidol dose. The initial conversion and any additional oral medicine require individual planning; there is no universal fixed pill-bridge duration in that label.

A known helpful response to haloperidol is relevant when considering it. Discuss stiffness, tremor, restlessness, involuntary movements, and heart-rhythm concerns. Parkinson disease and dementia with Lewy bodies are contraindications. Liver impairment also affects planning. Generic access can be useful, but an older medicine is not automatically either the best value or the wrong choice. Ask how its specific benefits and burdens compare for you.[15]

Fluphenazine decanoate

Fluphenazine decanoate is a generic long-acting medicine for people needing prolonged treatment of chronic psychotic illness, including schizophrenia. Its US label permits muscle or under-the-skin injection. The interval and conversion from shorter-acting treatment are individualized; a single timetable does not fit everyone.

Its longstanding use does not make monitoring optional. Movement problems, sedation, blood-pressure effects, and other warnings require review. The label precludes use with liver damage or blood disorders and says it is not intended for children under 12. That wording differs from newer adult-only product indications and should not be treated as a broad pediatric recommendation. Ask why this medicine fits your prior response and health history, and which route and interval the clinician proposes.[16]

Comparing LAI side effects without a false ranking

Practical fit: connect the schedule to your week

Drug effects: what deserves attention

These are discussion priorities, not a ranking or complete warning list. Effects vary by dose, formulation, health history, and person. The VA/DoD guideline describes differences in movement, weight/metabolic, sedation, and cardiac effects across antipsychotics.[24]

Daily pills and injections: different strengths

Neither route guarantees success. The right choice includes your preference and your ability to keep treatment going. Research comparisons also depend on the study design and setting, as Part 1 explains.[25]

An actual head-to-head trial is more useful than lining up percentages from unrelated labels. In ACLAIMS, 311 adults with schizophrenia or schizoaffective disorder were randomized to monthly paliperidone or haloperidol injections, with treatment planned for up to two years. The study did not find a statistically significant difference in treatment failure, an outcome including hospitalization and other signs of inadequate benefit. Paliperidone produced more weight gain and prolactin elevation; haloperidol produced greater restlessness. The uncertainty did not rule out a meaningful effectiveness difference.[26]

This does not rank every injection or predict your response. It shows why efficacy, physical health, and comfort must be considered together. “Newer,” “generic,” “under the skin,” and “fewer visits” each describe one feature. None settles the whole decision.

Generics, access, and new developments

Generic paliperidone approval is different from commercial supply. FDA records show that Teva received the first generic approval for monthly paliperidone palmitate on July 6, 2021, but that does not confirm current U.S. pharmacy stock. Confirm the actual product with the clinic or pharmacist. Similarly, an FDA notice describes discontinuation of particular Fresenius Kabi haloperidol presentations, not all haloperidol decanoate.[27,28]

Weltruza (olanzapine), approved October 8, 2026, is a monthly under-the-skin olanzapine injection for adults with schizophrenia. It needs no loading dose and no supplemental oral olanzapine at the start, and it has no required observation period after each injection. Its label still says the risk of the severe sedation or delirium reaction seen with Zyprexa Relprevv is currently unknown. Teva said it would be available in the coming weeks, so confirm supply before scheduling a first dose. Our Weltruza guide covers it in full.[13,29,30]

Questions to bring to the visit

Can I choose the longest interval immediately? Usually not for TRINZA or HAFYERA. Their labels require qualifying prior treatment. Other longer-interval products have their own starts.[4,17]

Will I still need pills? Possibly during initiation, or for another part of treatment. The exact product and your situation determine the plan. A one-day start still includes an oral dose for the aripiprazole products described above.[5,8,9]

Are injections within one drug family interchangeable? They can differ in release, dose, route, and start. Ask for a written prescriber-led transition plan rather than treating the brand name as a minor detail.

How should I narrow the choices? Bring the names of medicines that have helped, the effects you most want to avoid, and your appointment constraints. Ask: “Which two options fit my diagnosis and prior response, and what would make you choose one over the other?”

Related reading on NP FADY

• Long-Acting Antipsychotics: How They Work and Who They Help
• Living With Antipsychotic Injections: Safety and Family Support
• Cobenfy for schizophrenia: benefits, side effects, and dosing
• Bipolar and schizophrenia medicines in pregnancy and breastfeeding
• Why two opposite medicines both target dopamine

Educational disclaimer

This article is for education. It does not diagnose any condition, choose a medication for anyone, or replace the judgment of the clinician who knows your history. Do not start, stop, or change any medication without your prescriber. If there is imminent danger, or you cannot keep yourself or someone else safe, call 911 or go to the nearest emergency department. In the United States, call or text 988, or chat at 988lifeline.org, for any mental-health crisis. For a suspected overdose or accidental ingestion, call Poison Help at 1-800-222-1222. Regulatory and numeric claims in this article were checked against current FDA labeling and primary studies on September 30, 2026. Labels, approvals, and availability change; confirm current status with your prescriber or pharmacist before acting on anything here.

References

1. INVEGA SUSTENNA prescribing information. Janssen/Johnson & Johnson; FDA labeling reproduced by DailyMed. PI revised 2025-01; instructions 2025-02. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554 Accessed 2026-09-30.
2. ERZOFRI prescribing information. Luye Pharma / DailyMed. 2025-03 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492bf9dd-868e-421a-92db-8cca8973aac1 Accessed 2026-09-30.
3. UZEDY prescribing information. Teva; FDA labeling reproduced by DailyMed. PI revised 2025-10. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=734eb776-4be0-4808-834b-0d8b0f9e021e Accessed 2026-09-30.
4. INVEGA HAFYERA prescribing information. Janssen / DailyMed. 2025-01 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cd61892-d2cb-434d-83ed-5c1b2c4e7a0b Accessed 2026-09-30.
5. ABILIFY MAINTENA prescribing information and Medication Guide. Otsuka; FDA labeling reproduced by DailyMed. DailyMed label version March 24, 2026; Medication Guide revised 03/2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6 Accessed 2026-09-30.
6. RISPERDAL CONSTA prescribing information. Janssen / DailyMed. 2025-01 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb34ee82-d2c2-43b8-ba21-2825c0954691 Accessed 2026-09-30.
7. RYKINDO prescribing information. Luye Pharma / DailyMed. 2026-01 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58534c96-96f5-4c2e-a061-92d4506aee91 Accessed 2026-09-30.
8. ABILIFY ASIMTUFII prescribing information. Otsuka / DailyMed. 2025-03 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da4c07fd-1130-4341-bb44-63acfa4162be Accessed 2026-09-30.
9. ARISTADA prescribing information. Alkermes / DailyMed. 2025-01 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17a8d11b-73b0-4833-a0b4-cf1ef85edefb Accessed 2026-09-30.
10. ARISTADA INITIO prescribing information. Alkermes / DailyMed. 2025-01 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403 Accessed 2026-09-30.
11. ZYPREXA RELPREVV prescribing information. H2-Pharma/Cheplapharm; FDA labeling reproduced by DailyMed. PI revised 2026-05; Medication Guide 2026-01. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11544cba-64a9-49cb-8d74-da228053b252 Accessed 2026-09-30.
12. Discontinue availability for PERSERIS. Indivior. Effective May 31, 2026; notice undated. https://www.indivior.com/our-products/discontinue-availability-of-perseris.html Accessed 2026-09-30.
13. Teva announces U.S. Food and Drug Administration (FDA) approval of WELTRUZA (olanzapine) for extended-release injectable suspension. Teva. October 9, 2026. https://www.tevausa.com/news-and-media/press-releases/teva-announces-u.s.-food-and-drug-administration-fda-approval-of-weltruza-olanzapine-for-extended-re/ Accessed 2026-10-13.
14. Psychosis and schizophrenia in adults: prevention and management, CG178, recommendations. NICE. 2014 guideline; LAI recommendation amended 2022; current official recommendations retrieved. https://www.nice.org.uk/guidance/cg178/chapter/recommendations Accessed 2026-09-30.
15. Haloperidol decanoate prescribing information. Lifestar Pharma / DailyMed. 2026-06 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a96195e-97cd-4161-96e0-494a1636fa9c Accessed 2026-09-30.
16. Fluphenazine decanoate prescribing information. Hikma / DailyMed. 2025-01 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311 Accessed 2026-09-30.
17. INVEGA TRINZA prescribing information. Janssen / DailyMed. 2025-01 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c39e65d7-fa44-4e4c-8b12-a654d3ed0eae Accessed 2026-09-30.
18. Risperidone extended-release injectable suspension prescribing information. Lupin / DailyMed. 2026-02 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b462e48c-ef1d-4591-8fca-6b5829d8ed90 Accessed 2026-09-30.
19. Lupin launches risperidone long-acting injectable in the U.S.. Lupin. November 14, 2025. https://lupin.com/US/media/lupin-launches-risperidone-long-acting-injectable-with-180-day-cgt-exclusivity-in-the-u-s-the-first-product-from-its-proprietary-long-acting-injectable-platform-precision-sphere Accessed 2026-09-30.
20. Risperidone extended-release injectable suspension prescribing information. Amneal / DailyMed. 2025-07 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d526af85-ee70-4657-a27e-d451027ffd9e Accessed 2026-09-30.
21. PERSERIS prescribing information (historical formulation details). Indivior / DailyMed. 2025-01 (full prescribing-information revision; retrieved September 30, 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4f21b1a-5691-4b14-a56d-651962d06f39 Accessed 2026-09-30.
22. FDA Drug Safety Communication FDA warns about new impulse-control problems associated with aripiprazole. US Food and Drug Administration. 2016-05-03; FDA-linked archive capture 2025-12-14, accessed 2026-09-30. https://web.archive.org/web/20251214114626/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-new-impulse-control-problems-associated-mental-health Accessed 2026-09-30.
23. ZYPREXA RELPREVV Supplement Approval and REMS Requirements NDA022173 S39. US Food and Drug Administration. 2021-04-28; Reference ID 4786995. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/022173Orig1s039ltr.pdf Accessed 2026-09-30.
24. VA/DoD Clinical Practice Guideline for Management of First-Episode Psychosis and Schizophrenia. US Department of Veterans Affairs / Department of Defense. April 2023, Version 2.0. https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/MH/scz/VA-DOD-CPG-Schizophrenia-CPG_Finalv231924.pdf Accessed 2026-09-30.
25. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. 2021-04-13 online; Lancet Psychiatry 8:387-404. DOI 10.1016/S2215-0366(21)00039-0 PMID 33862018 https://pubmed.ncbi.nlm.nih.gov/33862018/ Accessed 2026-09-30.
26. Effectiveness of Paliperidone Palmitate vs Haloperidol Decanoate for Maintenance Treatment of Schizophrenia: A Randomized Clinical Trial. McEvoy JP, Byerly M, Hamer RM, et al.. 2014-05-21; JAMA 311:1978-1987. DOI 10.1001/jama.2014.4310 PMID 24846035 https://jamanetwork.com/journals/jama/fullarticle/1872816 Accessed 2026-09-30.
27. 2021 First Generic Drug Approvals. FDA. Approval July 6, 2021; record retrieved 2026-09-30. https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2021-first-generic-drug-approvals Accessed 2026-09-30.
28. Haloperidol decanoate discontinuation record: Fresenius Kabi presentations. FDA. Posted January 9, 2026; retrieved September 30, 2026. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Haloperidol+Decanoate+Injection&st=d&tab=tabs-2 Accessed 2026-09-30.
29. NDA 219007 approval letter, WELTRUZA. US Food and Drug Administration. Signed October 8, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219007Orig1s000ltr.pdf Accessed 2026-10-13.
30. WELTRUZA (olanzapine) for extended-release injectable suspension prescribing information. Teva Neuroscience. Revised October 2026. https://www.weltruza.com/globalassets/weltruza/prescribing-information.pdf Accessed 2026-10-13.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, or chat at 988lifeline.org, available 24/7, free and confidential. En español: marque 988 y oprima 2, o envíe AYUDA al 988. Deaf or hard of hearing: 988 videophone (ASL) or TTY 711 then 988. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.